-
Mashup Score: 25Qualtrics Survey | Qualtrics Experience Management - 3 month(s) ago
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
Source: iaslc.co1.qualtrics.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Qualtrics Survey | Qualtrics Experience Management - 3 month(s) ago
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
Source: iaslc.co1.qualtrics.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 103Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - 3 month(s) ago
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favourable trend for Tagrisso, although data were not mature
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 102Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - 3 month(s) ago
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favourable trend for Tagrisso, although data were not mature
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 100Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - 3 month(s) ago
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favourable trend for Tagrisso, although data were not mature
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 100Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - 3 month(s) ago
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favourable trend for Tagrisso, although data were not mature
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 150FDA approves osimertinib - 3 month(s) ago
FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14Biomarkers in Lung Cancer: Barriers to Implementation | IASLC - 3 month(s) ago
The IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2017 that found one-third of oncologists were unaware of evidence-based gu …
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet-
It was an honor to join the one & only great host/expert Dr. @StephenVLiu & amazing colleagues, Drs @DeboraBrunoMD1 @MattSmeltzer in this special @IASLC “Lung Cancer Considered” #Podcast on: “Biomarkers in #LungCancer.” Tune in👇🏼& Plz take the survey. https://t.co/8BbJfDmHtZ https://t.co/JgODj4vO6g https://t.co/fO0KKB1TRX
-
-
Mashup Score: 145FDA approves osimertinib - 3 month(s) ago
FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 132FDA approves osimertinib - 3 month(s) ago
FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
🔥🚨The International Association for the Study of Lung Cancer @IASLC needs your help completing a SHORT survey on a very important topic: “#Biomarker Testing in #LungCancer” Survey will help improve #Care for #Patients. Please share. Survey link👇🏼 https://t.co/X4zxmX3dSL https://t.co/xZ2pPJZRi8